Publications by authors named "Eric Ruby"
Article Synopsis
- The study investigates ABI-H0731, a new drug aimed at treating hepatitis B virus (HBV) by targeting the HBV core protein, to potentially achieve a functional cure.
- The research was conducted in two phases: Phase 1 involved healthy adults receiving varying single or multiple doses of the drug to assess safety and tolerability, while Phase 2 focused on adults with chronic HBV receiving daily doses for 28 days.
- Results showed that the drug was assessed for its safety, pharmacokinetics, and antiviral effects, with findings being made available under the ClinicalTrials.gov identifier NCT02908191.
Background & Aims: Although treatment of hepatitis C virus (HCV) and HCV-genotype-4 (GT4) has become very effective, it remains very expensive, and affordable options are needed, especially in limited resource countries. The aim of this study was to assess the efficacy and safety of the combination of ravidasvir (an NS5A inhibitor) and sofosbuvir to treat patients with chronic HCV-GT4 infection.
Methods: A total of 300 patients with HCV-GT4 infection were recruited in three groups: treatment-naïve patients with or without compensated Child-A cirrhosis (Group 1); interferon-experienced patients without cirrhosis (Group 2); and interferon-experienced patients with cirrhosis (Group 3).